IMUNON, Inc. (NASDAQ:
IMNN), a clinical-stage drug-development company focused
on developing non-viral DNA-mediated immuno-oncology therapies and
next-generation vaccines, today announced financial results for the
three and six months ended June 30, 2023. The Company also provided
an update on its clinical development programs with IMNN-001
(formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy
in Phase 2 clinical development for the treatment of advanced-stage
ovarian cancer, and on its PlaCCine modality, a proprietary mono-
or multi-cistronic non-viral and synthetic DNA technology for the
expression of pathogen antigens, being evaluated in preclinical
studies for the development of next-generation vaccines.
Highlights of the second quarter of 2023 and
recent weeks include:
- On track to submit an
Investigational New Drug (IND) application in the first quarter of
2024 for a proposed Phase 1/2 program with a seasonal COVID-19
booster vaccine, following positive pre-IND feedback from the U.S.
Food and Drug Administration (FDA)
- Reported data suggesting PlaCCine
vaccines elicit robust and more durable T-cell responses than
commercial mRNA vaccines, signaling that these vaccines may provide
greater protection against reinfection, hospitalization or
death
- Unveiled new current Good
Manufacturing Practices (cGMP) clinical materials production
facility to support R&D efficiencies and
lower costs for infectious disease and
cancer vaccines, and non-viral
DNA-based immune-oncology therapies
- Reported cash and cash equivalents
of $24.1 million as of June 30, 2023, which along with planned
sales of State of New Jersey net operating losses (NOLs) is
expected to fund operations through 2024
“We have now successfully de-risked our PlaCCine
modality preclinically across many pathogens of interest by
demonstrating in animal models the immunogenicity and safety of our
vaccines. We have generated compelling data in SARS-CoV-2 and with
IMNN-101, a next-generation COVID-19 seasonal booster, and expect
to be in the clinic in first quarter of 2024. In addition, we have
generated excellent immunological responses for vaccines against
other pathogens of concern including monkeypox, flu and
arenaviruses. Our DNA vaccines are well positioned to become the
next generation of vaccines and I am excited about their potential
with the demonstration preclinically of durability of IgG antibody
response, without a booster dose, and higher T-cell activation than
mRNA vaccines. Another significant advantage over commercial mRNA
vaccines is the demonstration of more than 12 months stability at
standard refrigerated temperature of 4°C,” said Dr. Corinne Le
Goff, IMUNON’s President and Chief Executive Officer.
“Based on positive FDA feedback in July from a
pre-IND meeting for our seasonal COVID-19 booster vaccine, we are
on track to submit an IND application in the first quarter of 2024.
The FDA confirmed in a written response that our plug-and-play
strategy for our platform approach was acceptable. This confirms
the flexibility and versatility of our platform, which allows for
the rapid production and development of any vaccine simply by
changing the antigen coding cassette. In addition, we expect to
announce our next pathogen target for our PlaCCine modality in the
coming weeks.”
Dr. Le Goff continued, “In June we unveiled our
new pilot manufacturing capability for DNA plasmids and
nanoparticle delivery systems. Our scientists are now able to
select any protein from the human or pathogen proteomes to be
engineered. Our existing labs also have the ability to conduct
testing and to run experiments in a variety of animal disease
models. These internal capabilities will allow us to control both
the costs and the process. The objective of our vaccine program is
to establish the platform’s safety and efficacy in various Phase 1
studies, and then seek to license this powerful technology and/or
establish non-dilutive partnerships to develop vaccines for
pathogens of interest,” she added.
“We expect to reach several value-creating
milestones over the next six to 18 months. Among them is reporting
additional interim data on IMNN-001 from our OVATION 2 Study and
the combination study with bevacizumab in advanced ovarian cancer,
reporting topline data from the OVATION 2 Study, filing the IND for
our SARS-CoV-2 vaccine and announcing proof-of-concept vaccine data
for our next pathogen target. We intend to discuss all of this and
more during a virtual R&D Day event we are planning for this
fall,” Dr. Le Goff concluded.
RECENT
DEVELOPMENTS
PlaCCine:
Developing
the Prophylactic
Vaccines of the
Future
Publication of Preclinical Data
with PlaCCine DNA-based Vaccines Modality
Available Online on bioRxiv. In August
2023 the Company announced that a manuscript titled “Strong
immunogenicity & protection in mice with PlaCCine: A COVID-19
DNA vaccine formulated with a functional polymer” is available on
the preprint server bioRxiv [here]. The study used IMUNON’s
proprietary formulation against the spike proteins from two
SARS-CoV-2 variants, both alone and in combination. These results
add to the growing body of preclinical data confirming the efficacy
and superior desirable features of IMUNON’s PlaCCine vaccine
modality. Data from the study show:
- IMUNON’s proprietary formulation of
functionalized polymer protected DNA from degradation, while the
combination with an adjuvant led to an increase in protein
expression
- DNA formulated with PlaCCine
resulted in a DNA vaccine product that was stable for up to one
year at 4°C
- DNA formulated in PlaCCine resulted
in the induction of spike-specific neutralizing antibodies and
cytotoxic T cells
- In the in vivo challenge model, the
vaccine-induced immune response was capable of suppressing viral
replication
- Multiple inserts can be cloned into
the PlaCCine backbone (a plug-and-play strategy), therefore
allowing for an immune response with broader protection
Presentation at the
2023 Viruses and Cells – Gordon Research
Conference Describes Compelling
Preclinical Data
Showing
Continued
Durability of
Response Over
14 Months
with Humoral Immune Response
Increasing
Over Time.
In May 2023 Khursheed Anwer, Ph.D., IMUNON’s Executive Vice
President and Chief Science Officer, presented new PlaCCine
preclinical data at the 2023 Viruses and Cells – Gordon
Research Conference in Barcelona. Dr. Khursheed’s
presentation, titled “A Novel DNA Vaccine Approach to Prophylactic
and Therapeutic Vaccines,” described IMUNON’S PlaCCine technology
platform for the development of next-generation vaccines, and is
available here.
Results from preclinical studies in a PlaCCine
COVID-19 vaccine demonstrated characteristics that address the
limitations of current commercial vaccines by offering enhanced
breadth of protection to emerging variants, persistence and robust
cellular immunity, as well as stability at workable temperatures.
Importantly, humoral immune responses specific to the SARS-CoV-2
spike antigen were persistent over a 14-month post-vaccination
period in mice, while the T-cell responses from PlaCCine COVID-19
vaccines after 14 months were higher than a commercial mRNA
vaccine. In another mouse study, the humoral response to a single
dose of a commercial mRNA vaccine plateaued within 14 days after
vaccination while the response continued to increase over time with
a PlaCCine vaccine, demonstrating improved durability. In addition,
PlaCCine was stable for at least nine months at refrigerated
temperatures and for at least one month at room temperature.
Presentation at
the Vaccine Technology Summit
2023 Describes Compelling Preclinical Data
Supporting Continued Development
of PlaCCine as a Differentiated,
Next-Generation Vaccine. In March 2023
Dr. Anwer presented data on the Company’s PlaCCine platform at the
Vaccine Technology Summit 2023 in Boston. Dr. Anwer’s presentation
is titled “A Novel DNA Vaccine Platform with Potential to Create
Next Generation Vaccines” and is available here.
Dr. Anwer reviewed the Company’s work in
advancing its PlaCCine modality and the promising preclinical data
generated to date. Among topics presented was the ability of this
multi-valent technology to achieve broad-spectrum immunity from a
single DNA plasmid with a synthetic delivery system that is
independent of virus, device or liquid nanoparticle formulations.
The data presented showed:
- Robust immunogenicity and
protection in SARS-CoV-2 models
- Durable cellular or humoral
responses detectable for more than 12 months
- Comparable protection activity to a
commercial mRNA vaccine in a booster-dose comparison
- Superior immune quality versus the
mRNA vaccine in a single-dose comparison
In addition, the PlaCCine modality had important
advantages for a commercial vaccine, including a shelf-life at 4⁰C
for greater than nine months, and the ability for simple, rapid and
scalable manufacturing.
IMNN-001
Immunotherapy
Presentation
at the American Association for
Cancer Research (AACR)
Describes Findings from Mouse
Model of
Peritoneally Disseminated
Ovarian Cancer that Suggest
Biweekly Dosing Regimen for Further Evaluation in Human Clinical
Studies. In April 2023 Jean Boyer, Ph.D.,
IMUNON’s Vice President of Preclinical Research, presented a poster
titled “Efficacy of IMNN-001, an Interleukin-12 Immune Gene
Therapy, at Different Dose Frequencies” at the AACR in Orlando,
which is available here.
Researchers concluded that IMNN-001 demonstrated
stimulation of the immune response in the ID8 ovarian tumor model.
Of the three dosing regimens tested, the once every 2-week regimen
demonstrated comparability to the weekly regimen while showing
superiority over the once every 3-week regimen, particularly with
respect to mortality and tumor burden. These findings suggest
exploring once every 2-week dosing of IMNN-001 in human studies,
which is already incorporated into the protocol of a new study
evaluating IMNN-001 in combination with bevacizumab in the
treatment of advanced ovarian cancer. This study is sponsored by
the Break Through Cancer Foundation.
Corporate Developments
IMUNON Unveils New
Manufacturing Facility at
Huntsville’s HudsonAlpha Biotech Campus. In June 2023, the
Company unveiled its new cGMP clinical materials production
facility on the Huntsville, Alabama campus of
the HudsonAlpha Institute for Biotechnology. The facility is
intended to support R&D efficiencies and lower development
costs for infectious disease and
cancer vaccines, and non-viral
DNA-based immune-oncology therapies. This new capability
complements the Company’s existing cGMP quality control facility
for testing clinical products at the Huntsville site.
IMUNON has designed and built its own
manufacturing capabilities to produce GMP-grade plasmid DNA
(pDNA) and DNA-facilitating agents to support Phase 1 clinical
studies with its PlaCCine infectious disease modality and its
IndiPlas and FixPlas cancer vaccine modalities. The new facility’s
specifications follow the 2008 FDA guidance cGMP for Phase 1
investigational drugs. The pDNA and DNA facilitating agents are key
components of the final vaccine formulation, with GMP fill and
finish carried out at a CDMO partner site.
IMUNON’s CEO Presents Business Overview
at BIO 2023 International Convention and Mass
General Brigham World Medical Innovation Forum 2023. Dr.
Le Goff provided an overview of IMUNON’s business progress to
an audience of investors and biopharmaceutical professionals at the
BIO 2023 International Convention and at the Mass General
Brigham World Medical Innovation Forum 2023, both in Boston. She
highlighted the strength of IMUNON’s leadership team, and the
status of the Company’s TheraPlas nucleic acid therapeutics
platform and its PlaCCine nucleic acid vaccine platform while
providing context on the promise of DNA as a therapeutic and a
vaccine. For the PlaCCine and TheraPlas technologies, Dr. Le
Goff described mechanisms of action and provided a closer look
at the promising clinical results generated to-date. She provided
background on the use of DNA in these medicines, characterizing its
performance in terms of durability, development speed and ease of
manufacturing, shipping and storage. Dr. Le Goff also
highlighted the potential
of IMNN-001 for the treatment of ovarian
cancer during a panel discussion. Dr. Le Goff’s presentation
is available here.
SECOND QUARTER
FINANCIAL RESULTS
IMUNON reported a net loss for the second
quarter of 2023 of $5.6 million, or $0.61 per share, compared with
a net loss of $6.0 million, or $0.87 per share, for the second
quarter of 2022. Operating expenses were $5.5 million for the
second quarter of 2023, a decrease of $0.6 million, or 10%, from
$6.1 million for the second quarter of 2022.
Net cash used for operating activities was $6.8
million for the second quarter of 2023 compared with $5.4 million
for the comparable prior-year period. The increase was primarily
due to the cash settlement in April 2023 along with related legal
fees for arbitration with a former contract manufacturer for
ThermoDox. Cash used by financing activities of $6.2 million during
the second quarter of 2023 resulted from the early repayment of the
Company’s loan facility with Silicon Valley Bank, offset by equity
sales under the Company’s At-the-Market Equity Facility. The
Company had $24.1 million in cash, investments and
accrued interest receivable as of June 30, 2023. Combined with $1.8
million in planned future sales of IMUNON’s State of New Jersey
NOLs, the Company believes it has sufficient capital resources to
fund its operations through 2024.
Research and development (R&D) expenses were
$3.1 million for the second quarter of 2023 compared with $3.2
million for the comparable period in 2022. R&D costs to support
the OVATION 2 Study as well as the Phase 3 OPTIMA Study decreased
to $0.3 million for the second quarter of 2023 compared with $0.8
million for the same period of 2022. Other clinical and regulatory
costs were $0.4 million for the second quarter of 2023 compared
with $0.7 million for the second quarter of 2022. R&D costs
associated with the preclinical development of the PlaCCine DNA
vaccine modality increased to $1.3 million for the second quarter
of 2023 compared with $0.6 million for the same period of 2022.
R&D costs associated with the preclinical development of
IMNN-001 decreased to $0.4 million for the second quarter of 2023
compared with $0.8 million for the same period of 2022. Chemistry,
manufacturing and controls (CMC) costs increased to $0.7 million
for the second quarter of 2023 compared with $0.3 million for the
second quarter of 2022 due to higher costs related to the
development of in-house pilot manufacturing capabilities for DNA
plasmids and nanoparticle delivery systems.
General and administrative expenses were $2.3
million for the second quarter of 2023 compared with $2.9 million
for the comparable prior-year period. The decrease was primarily
due to lower non-cash stock-compensation expense and lower
professional fees, including legal fees to defend various lawsuits
filed after the announcement in July 2020 of the Phase 3 OPTIMA
Study results, offset by higher compensation expenses related to
the CEO succession plan announced in July 2022 and higher staffing
costs.
Other non-operating expenses were $85 thousand
for the second quarter of 2023 compared with $65 thousand for the
prior-year period. The Company incurred early debt extinguishment
expense on its loan facility with Silicon Valley Bank totalling
$0.3 million, offset by higher investment income from the Company’s
short-term investments due to higher returns on these
investments.
FIRST HALF
FINANCIAL RESULTS
For the six months ended June 30, 2023, the
Company reported a net loss of $11.2 million, or $1.28 per share,
compared with a net loss of $16.5 million, or $2.59 per share, for
the same period of 2022. Operating expenses were $11.2 million for
the first six months of 2023, a decrease of $0.9 million, or 8%,
from $12.1 million for the same period of 2022.
Net cash used for operating activities was $10.8
million for the first six months of 2023 compared with $13.4
million for the same period in 2022. The decrease was primarily due
to the one-time payment of $4.5 million in interest expense
resulting from the sale and subsequent redemption of $30 million of
Series A & B convertible redeemable preferred stock in the
first quarter of 2022. The Company’s projected cash utilization for
the balance of 2023 is approximately $4.5 million per quarter. Cash
used by financing activities of $3.7 million during the first six
months of 2023 resulted from the early repayment of the Company’s
loan facility with Silicon Valley Bank ($6.4 million), offset by
sales of equity under the Company’s At-the-Market Equity Facility
($2.7 million). The Company also received net proceeds of $1.6
million from the sale of its unused New Jersey NOLs in the first
quarter of 2023.
R&D expenses were $5.8 million for the first
six months of 2023 compared with $6.3 million for the comparable
period in 2022. R&D costs to support the OVATION 2 Study as
well as the Phase 3 OPTIMA Study decreased to $0.6 million for the
first six months of 2023 compared with $1.3 million for the
comparable 2022 period. Other clinical and regulatory costs were
$0.7 million for the first six months of 2023 compared with $1.5
million for the same period of 2022. R&D costs associated with
the preclinical development of the PlaCCine DNA vaccine modality
increased to $2.3 million for the first six months of 2023 compared
with $1.2 million for the same period of 2022. R&D costs
associated with the preclinical development of IMNN-001 decreased
to $0.8 million for the first half of 2023 compared with $1.7
million for the same period of 2022. CMC costs increased to $1.4
million for the first six months of 2023 compared with $0.6 million
for the comparable 2022 period due to higher costs related to the
development of in-house pilot manufacturing capabilities for DNA
plasmids and nanoparticle delivery systems.
General and administrative expenses were $5.4
million for the first six months of 2023 compared with $5.7 million
for the same period of 2022. The $0.3 million decrease was
primarily attributable to lower non-cash stock-compensation
expense, offset by higher compensation expenses related to the CEO
succession plan announced in July 2022 and higher staffing
costs.
Other non-operating income was $9 thousand for
the first six months of 2023 compared with $4.7 million for the
comparable prior-year period. The decrease was primarily
attributable to the one-time payment of $4.5 million in interest
expense resulting from the sale and subsequent redemption of $30
million of Series A & B convertible redeemable preferred stock
in the first quarter of 2022.
VIRTUAL
R&D DAY
EVENT
IMUNON management along with several guest key
opinion leaders plan to host a virtual R&D Day event this fall
to discuss the Company’s progress in developing its PlaCCine
platform, IMNN-001, and other achievements. Presenters will also
review strategic plans and opportunities for IMUNON. Additional
information including date, time of day and instructions to
participate will be announced in a separate news release.
CONFERENCE CALL AND WEBCAST
The Company is hosting a conference call to
provide a business update, discuss second quarter 2023 financial
results and answer questions at 11:00 a.m. EDT today. To
participate in the call, please dial 866-777-2509 (Toll-Free/North
America) or 412-317-5413 (International/Toll) and ask for the
IMUNON Second Quarter 2023 Earnings Call. A live webcast of the
call will be available here.
The call will be archived for replay until
August 24, 2023. The replay can be accessed at 877-344-7529 (U.S.
Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088
(International Toll), using the replay access code 1202020. A
webcast of the call will be available here for 90 days.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective, and durable responses across a broad
array of human diseases, constituting a differentiating approach
from conventional therapies. IMUNON is developing its non-viral DNA
technology across 4 modalities. The first modality, Theraplas®, is
developed for the coding of proteins and cytokines in the treatment
of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine® is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, Fixplas®, concerns the application of our DNA technology
to produce universal cancer vaccines also called tumor associated
antigen cancer vaccines. Finally, the fourth modality, which is
still in the discovery phase, Indiplas®, will focus on the
development of personalized cancer vaccines, or neoepitope cancer
vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical studies to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
609-482-2455 |
Kgolodetz@lhai.com |
jchurch@imunon.com |
|
(Tables to Follow)
IMUNON, Inc.Condensed
Statements of Operations(in thousands except per
share amounts)
|
|
Three Months EndedJune 30, |
|
|
Six Months EndedJune 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing
revenue |
|
$ |
- |
|
|
$ |
125 |
|
|
$ |
- |
|
|
$ |
250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
3,134 |
|
|
|
3,226 |
|
|
|
5,754 |
|
|
|
6,322 |
|
General and administrative |
|
|
2,340 |
|
|
|
2,877 |
|
|
|
5,405 |
|
|
|
5,748 |
|
Total operating expenses |
|
|
5,474 |
|
|
|
6,103 |
|
|
|
11,159 |
|
|
|
12,070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations |
|
|
(5,474 |
) |
|
|
(5,978 |
) |
|
($ |
11,159 |
) |
|
|
(11,820 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment income |
|
|
281 |
|
|
|
40 |
|
|
|
535 |
|
|
|
52 |
|
Interest expense |
|
|
(37 |
) |
|
|
(105 |
) |
|
|
(197 |
) |
|
|
(4,751 |
) |
Loss on debt extinguishment |
|
|
(329 |
) |
|
|
- |
|
|
|
(329 |
) |
|
|
- |
|
Other income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2 |
|
Total other (expense) income, net |
|
|
(85 |
) |
|
|
(65 |
) |
|
|
9 |
|
|
|
(4,697 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(5,559 |
) |
|
$ |
(6,043 |
) |
|
$ |
(11,150 |
) |
|
$ |
(16,517 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common
share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.61 |
) |
|
$ |
(0.87 |
) |
|
$ |
(1.28 |
) |
|
$ |
(2.59 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
9,137 |
|
|
|
6,982 |
|
|
|
8,711 |
|
|
|
6,373 |
|
IMUNON, Inc.Selected
Balance Sheet Information(in
thousands)
|
|
June 30,2023 |
|
|
December 31,2022 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
6,611 |
|
|
$ |
11,493 |
|
Investment securities and interest receivable |
|
|
17,480 |
|
|
|
21,384 |
|
Money market investments, restricted cash |
|
|
- |
|
|
|
1,500 |
|
Advances, deposits and other current assets |
|
|
2,640 |
|
|
|
2,778 |
|
Total current assets |
|
|
26,731 |
|
|
|
37,155 |
|
|
|
|
|
|
|
|
|
|
Property and equipment |
|
|
651 |
|
|
|
548 |
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
Restricted cash invested in money market account |
|
|
- |
|
|
|
4,500 |
|
Deferred tax asset |
|
|
- |
|
|
|
1,567 |
|
Operating lease right-of-use assets, deposits, and other
assets |
|
|
1,339 |
|
|
|
206 |
|
Total other assets |
|
|
1,339 |
|
|
|
6,273 |
|
Total assets |
|
$ |
28,721 |
|
|
$ |
43,976 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
5,846 |
|
|
$ |
8,381 |
|
Note payable – current portion |
|
|
- |
|
|
|
1,425 |
|
Operating lease liabilities – current portion |
|
|
278 |
|
|
|
231 |
|
Total current liabilities |
|
|
6,124 |
|
|
|
10,037 |
|
|
|
|
|
|
|
|
|
|
Notes payable – noncurrent portion |
|
|
- |
|
|
|
4,611 |
|
Operating lease liabilities – noncurrent portion |
|
|
1,082 |
|
|
|
- |
|
Total
liabilities |
|
|
7,206 |
|
|
|
14,648 |
|
Stockholders’
equity |
|
|
|
|
|
|
|
|
Common stock |
|
|
92 |
|
|
|
74 |
|
Additional paid-in capital |
|
|
401,164 |
|
|
|
397,980 |
|
Accumulated other comprehensive gain (loss) |
|
|
162 |
|
|
|
27 |
|
Accumulated deficit |
|
|
(379,818 |
) |
|
|
(368,668 |
) |
|
|
|
21,600 |
|
|
|
29,413 |
|
Less: Treasury stock |
|
|
(85 |
) |
|
|
(85 |
) |
Total stockholders’
equity |
|
|
21,515 |
|
|
|
29,328 |
|
Total liabilities and
stockholders’ equity |
|
$ |
28,721 |
|
|
$ |
43,976 |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024